Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Biomolecules in Drug Resistance in Cancer and Metastatic Cancers
share announcement

Biomolecules in Drug Resistance in Cancer and Metastatic Cancers

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 7675

Special Issue Editor

Prof. Dr. Wenguo Jiang

E-Mail Website
Guest Editor
School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
Interests: metastasis; molecular cancer biology; molecular prognostics; surgical oncology; novel therapeutics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Resistance to drug therapies remains a major challenge to the success of cancer treatment and in particular in the treatment of metastatic cancers. Drug resistance often leads to treatment failure, disease progression, and the development of metastasis. The current Special Issue is devoted to publishing high-quality research addressing the mechanisms of drug resistance, molecules that lead to the development or indeed sensitivity to drug treatment in cancers and metastatic cancers, molecular methods in predicting resistance or sensitivity to drug therapies. Studies addressing ways to overcome drug resistance, both laboratory and clinical research, are also considered. Drug resistance includes to chemotherapies, hormonal therapies, target therapies, and novel therapeutics. Studies reporting genetic, molecular, cellular, and clinical findings on drug resistance in cancer and metastatic cancer, and reports on methods to sensitize cancer and cancer cells to drug treatment are welcome. Original research articles and review articles will be considered.

Prof. Dr. Wen Jiang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Drug resistance
  • Metastatic cancer treatment
  • Metastasis
  • Chemotherapies
  • Target therapies
  • Molecular Prediction of Resistance
  • Molecular Evaluation of Resistance

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

23 pages, 3578 KiB  
Review
Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer
by Megan M. Jorgensen and Pilar de la Puente
Biomolecules 2022, 12(2), 217; https://doi.org/10.3390/biom12020217 - 27 Jan 2022
Cited by 19 | Viewed by 7125
Abstract
Leukemia Inhibitory Factor (LIF) is a member of the IL-6 cytokine family and is expressed in almost every tissue type within the body. Although LIF was named for its ability to induce differentiation of myeloid leukemia cells, studies of LIF in additional diseases [...] Read more.
Leukemia Inhibitory Factor (LIF) is a member of the IL-6 cytokine family and is expressed in almost every tissue type within the body. Although LIF was named for its ability to induce differentiation of myeloid leukemia cells, studies of LIF in additional diseases and solid tumor types have shown that it has the potential to contribute to many other pathologies. Exploring the roles of LIF in normal physiology and non-cancer pathologies can give important insights into how it may be dysregulated within cancers, and the possible effects of this dysregulation. Within various cancer types, LIF expression has been linked to hallmarks of cancer, such as proliferation, metastasis, and chemoresistance, as well as overall patient survival. The mechanisms behind these effects of LIF are not well understood and can differ between different tissue types. In fact, research has shown that while LIF may promote malignancy progression in some solid tumors, it can have anti-neoplastic effects in others. This review will summarize current knowledge of how LIF expression impacts cellular function and dysfunction to help reveal new adjuvant treatment options for cancer patients, while also revealing potential adverse effects of treatments targeting LIF signaling. Full article
(This article belongs to the Special Issue Biomolecules in Drug Resistance in Cancer and Metastatic Cancers)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop